Technical Analysis for CRDL - Cardiol Therapeutics Inc.

Grade Last Price % Change Price Change
B 4.5 -6.25% -0.30
CRDL closed up 5.96 percent on Monday, September 27, 2021, on 2.48 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A N/A Up
Historical CRDL trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish -6.25%
Pocket Pivot Bullish Swing Setup -6.25%
New 52 Week High Strength -6.25%
Stochastic Reached Overbought Strength -6.25%
Upper Bollinger Band Walk Strength -6.25%
Wide Bands Range Expansion -6.25%
Above Upper BB Strength -6.25%
Overbought Stochastic Strength -6.25%
Up 3 Days in a Row Strength -6.25%
Up 4 Days in a Row Strength -6.25%
Older End-of-Day Signals for CRDL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 2 hours ago
Down 3% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cardiol Therapeutics Inc. Description

Cardiol Therapeutics Inc. (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (“CVD”). The Company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease. Cardiol has filed an investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.


Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic

Is CRDL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.9
52 Week Low 2.3001
Average Volume 726,966
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 4.02
10-Day Moving Average 4.19
Average True Range 0.34
ADX 57.42
+DI 34.29
-DI 8.77
Chandelier Exit (Long, 3 ATRs) 3.87
Chandelier Exit (Short, 3 ATRs) 4.13
Upper Bollinger Bands 4.66
Lower Bollinger Band 3.38
Percent B (%b) 1.11
BandWidth 31.71
MACD Line 0.39
MACD Signal Line 0.37
MACD Histogram 0.0241
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.34
Resistance 3 (R3) 5.31 5.11 5.25
Resistance 2 (R2) 5.11 4.97 5.12 5.22
Resistance 1 (R1) 4.95 4.88 5.03 4.98 5.19
Pivot Point 4.75 4.75 4.79 4.76 4.75
Support 1 (S1) 4.59 4.61 4.67 4.62 4.41
Support 2 (S2) 4.39 4.52 4.40 4.38
Support 3 (S3) 4.23 4.39 4.35
Support 4 (S4) 4.26